Sharecare, Inc.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Sharecare disclosed on March 29, 2024, admitted its failure to maintain appropriate controls over financial reporting and revenue recognition. Based on this news, shares of Sharecare fell by more than 28% in intraday trading on April 1, 2024.

-->

Sotera Health Company

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sotera Health Company (“Sotera” or “the Company”) (NASDAQ: SHC) for violations of the securities laws.

-->

Equinix, Inc.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Equinix is the subject of a report released by Hindenburg Research on March 20, 2024, titled: “Equinix Exposed: Major Accounting Manipulation, Core Business Decay And Selling an AI Pipe Dream As Insiders Cashed Out Hundreds of Millions.” According to the report Hindenburg’s “investigation, which included a review of financial and litigation records and interviews with 37 former Equinix employees, industry experts and competitors, revealed that Equinix manipulates its accounting for AFFO (“adjusted funds from operations”), the key profitability metric for REITs. We estimate this metric was overstated by at least 22% in 2023 alone.”

-->

Inari Medical, Inc.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Inari filed an Annual Report on Form 10-K on February 28, 2024, stating, “on December 2023, we received a civil investigative demand (“CID”) from the U.S. Department of Justice, Civil Division, in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act (the “Investigation”). The CID requests information and documents primarily relating to meals and consulting service payments provided to health care professionals (“HCPs”). We are cooperating with the Investigation. We are unable to express a view at this time regarding the likely duration, or ultimate outcome, of the Investigation or estimate the possibility of, or amount or range of, any possible financial impact. Depending on the outcome of the Investigation, there may be a material impact on our business, results of operations, or financial condition.”

-->

Planet Fitness, Inc.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Planet Fitness is the subject of an article published by Benzinga on March 19, 2024, titled: “’Give Planet Fitness The Bud Light Treatment’ — Calls Grow To Boycott Gym After String Of Sexual Abuse From Men In Women’s Bathrooms.” The articles claims that, “Growing concerns and controversy surrounding Planet Fitness’s inclusive policies have sparked significant debate and calls for boycotts, reminiscent of the backlash against Bud Light for its marketing decisions.” Based on this news, shares of Planet Fitness traded down sharply across several days.

-->

Lifecore Biomedical, Inc.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Lifecore announced on March 20, 2024, that its Board of Directors had concluded its review of strategic alternatives, in which it “unanimously concluded that the best way to maximize value for stockholders at this time is to continue executing on the Company’s standalone strategic plan.” The Company also announced a leadership transition by naming a new CEO. Based on this news, shares of Lifecore fell by 35.6% in morning trading on the same day.

-->

Spruce Biosciences, Inc.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Spruce is the subject of a Seeking Alpha report published on March 13, 2024. According to the report, the Company’s “stock plunged 75% in post-market trading Tuesday on news that the company plans to cut 21% of its workforce in the wake of a failed Phase 2 study for its drug candidate tildacerfont.” The report continues, “The biotech company said the study, called CAHmelia-203, failed to meet its primary endpoint and was being terminated as a result. The study had been evaluating tildacerfont in the treatment of adult classic congenital adrenal hyperplasia, or CAH, with severe hyperandrogenemia.”

-->

Dollar Tree, Inc.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Dollar Tree is the subject of a report by Bloomberg published on March 13, 2024. According to the report, the Company “plans to shutter about 1,000 stores in an effort to improve profitability as the discount retailer battles a spate of litigation and other headwinds.” Based on this news, shares of Dollar Tree fell by more than 15% in morning trading on the same day.

-->

ACADIA Pharmaceuticals Inc.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Acadia is the subject of an Investor’s Business Daily report published on March 12, 2024. According to the report, the Company “had been hoping its antipsychotic, Nuplazid, would make a difference for people with the negative symptoms of schizophrenia.” The report continues, “But in the Phase 3 study called Advance-2, placebo patients had an 11.1-point improvement on a scale measuring the negative symptoms of schizophrenia. Nuplazid recipients had an 11.8-point improvement.” Based on this news, shares of Acadia fell more than 17% in morning trading on the same day.

-->

P10, Inc.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of P10, Inc. (“P10” or “the Company”) (NYSE: PX) for violations of the securities laws.

-->